Category Archives: Stem Cell Medicine

Citius Pharmaceuticals Brings on Myron S. Czuczman, M.D. as Chief Medical Officer (CMO) and Executive Vice President – Stockhouse

CRANFORD, N.J., July 14, 2020 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, announced today that Myron S. Czuczman, M.D., has joined the company as Chief Medical Officer (CMO) and Executive Vice President. Dr. Czuczman was most recently Therapeutic Area Head, Vice President, Clinical Research and Development Global Lymphoma/CLL Program at Celgene Corporation. At Celgene, he was responsible for worldwide clinical development in Lymphoma/CLL and for the development of all compounds from Proof-of-Principle through registration globally.

Myron Holubiak, Citius CEO stated, "We are honored to have a colleague as qualified as Dr. Czuczman join the Citius team. He will be enormously helpful in furthering our development program for our planned iPSC-derived mesenchymal stem cell (iMSC) for the treatment of ARDS associated with CoVid-19. This, coupled with the advanced Phase 3 trials underway for Mino-Lok® and preparing an IND for Mino-Wrap, add to the importance of bringing in an executive of Dr. Czuczman's expertise, experience, and caliber to the team."

Prior to his tenure at Celgene, Dr. Czuczman served as Chief, Lymphoma/Myeloma Service in the Department of Medicine and Head of the Lymphoma Translational Research Laboratory in the Immunology Department at Roswell Park Comprehensive Cancer Center in Buffalo, NY where he attained the title of tenured Professor of Medicine and Oncology prior to joining Celgene.

Dr. Czuczman received his M.D. from Pennsylvania State University of Medicine after graduating magna cum laude in Biochemistry from the University of Pittsburgh. He completed his Internal Medicine residency training at Weill Cornell North Shore University/MSKCC Program, followed by Medical Oncology/Hematology fellowship training at Memorial Sloan-Kettering Cancer Center in New York, NY.

Dr. Czuczman was a Founding Member and reviewer for the National Comprehensive Cancer Network (NCCN) Lymphoma Guidelines compendium panel for nearly twenty years and he has greater than 180 peer-reviewed publications. He is a Diplomate in Internal Medicine, and is Board Certified in Medical Oncology and received numerous awards and accolades during his academic career.

About Citius Pharmaceuticals, Inc. Citius is a late-stage specialty pharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on anti-infectives and cancer care. For more information, please visit http://www.citiuspharma.com.

About Mino-Lok® Mino-Lok® is an antibiotic lock solution being developed as an adjunctive therapy in patients with central line-associated bloodstream infections (CLABSIs) or catheter-related bloodstream infections (CRBSIs). CLABSIs/CRBSIs are very serious, especially in cancer patients receiving therapy through central venous catheters (CVCs) and in hemodialysis patients, for whom venous access presents a challenge. There are currently no approved therapies for salvaging infected CVCs.

About Citius iMSC Citius's planned mesenchymal stem cell therapy product is derived from a human induced pluripotent stem cell (iPSC) line generated using a proprietary mRNA-based (non-viral) reprogramming process. The iMSCs produced from this clonal technique are differentiated from adult donor-derived MSCs (bone marrow, placenta, umbilical cord, adipose tissue, or dental pulp) by providing genetic homogeneity. In in-vitro studies, iMSCs exhibit superior potency and high cell viability. The iMSCs secrete immunomodulatory proteins that may reduce or prevent pulmonary symptoms associated with acute respiratory distress syndrome (ARDS) in patients with COVID-19. The Citius iMSC is an allogeneic (unrelated donor) mesenchymal stem-cell product manufactured by expanding material from a master cell bank.

About Acute Respiratory Distress Syndrome (ARDS) ARDS is a type of respiratory failure characterized by rapid onset of widespread inflammation in the lungs. ARDS is a rapidly progressive disease that occurs in critically ill patients most notably now in those diagnosed with COVID-19. ARDS affects approximately 200,000 patients per year in the U.S., exclusive of the current COVID-19 pandemic, and has a 30% to 50% mortality rate. ARDS is sometimes initially diagnosed as pneumonia or pulmonary edema (fluid in the lungs from heart disease). Symptoms of ARDS include shortness of breath, rapid breathing and heart rate, chest pain (particularly while inhaling), and bluish skin coloration. Among those who survive ARDS, a decreased quality of life is relatively common.

Safe Harbor This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius. You can identify these statements by the fact that they use words such as "will," "anticipate," "estimate," "expect," "should," and "may" and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price.

Factors that could cause actual results to differ materially from those currently anticipated are: our ability to attract, integrate, and retain key personnel; our need for substantial additional funds; the risk of successfully negotiating within the option period a license agreement with Novellus, Inc. for our planned Novecite therapy for ARDS; risks associated with conducting clinical trials and drug development; the estimated markets for our product candidates and the acceptance thereof by any market; risks related to our growth strategy; risks relating to the results of research and development activities; uncertainties relating to preclinical and clinical testing; the early stage of products under development; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; our ability to identify, acquire, close and integrate product candidates and companies successfully and on a timely basis; our dependence on third-party suppliers; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

Contact:

Andrew Scott Vice President, Corporate Development (O) 908-967-6677 x105 ascott@citiuspharma.com

View original content:http://www.prnewswire.com/news-releases/citius-pharmaceuticals-brings-on-myron-s-czuczman-md-as-chief-medical-officer-cmo-and-executive-vice-president-301092921.html

SOURCE Citius Pharmaceuticals, Inc.

The rest is here:
Citius Pharmaceuticals Brings on Myron S. Czuczman, M.D. as Chief Medical Officer (CMO) and Executive Vice President - Stockhouse

Cellular Reprogramming Tools Market- By Type, Component, Industry, Region Market Size, Demand Forecasts, Company Profiles, Industry Trends and…

The Global Cellular Reprogramming Tools Market report offers users the detailed study of the market and its main aspects. The study on Global Cellular Reprogramming Tools Market, offers profound understandings about the Cellular Reprogramming Tools Market covering all the essential aspects of the market. The report provides competitive pipeline landscape of the Global Factors like production, market share, revenue rate, regions and key players define a market study start to end. This report gives an overview of market valued in the year 2019 and its growth in the coming years till 2025.

This study covers following key players: The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3. Celgene FUJIFILM Holdings BIOTIME Advanced Cell Technology Mesoblast Human Longevity Cynata STEMCELL Technologies Astellas Pharma Osiris Therapeutics EVOTEC Japan Tissue Engineering

Request a sample of this report @ https://www.orbisresearch.com/contacts/request-sample/4721627?utm_source=Yogi

The study is done with the help of analysis such as SWOT analysis and PESTEL analysis. It consists of the detailed study of current market trends along with the past statistics. The past years are considered as reference to get the predicted data for the forecast period. The report covers complete analysis of the Cellular Reprogramming Tools Market on the basis of regional and Global level. Various important factors such as market trends, revenue growth patterns market shares and demand and supply are included in almost all the market research report for every industry.

There are different marketing strategies that every marketer looks up to in order to ace the competition in the Global market. Some of the primary marketing strategies that is needed for every business to be successful are Passion, Focus, Watching the Data, Communicating the value To Your Customers, Your Understanding of Your Target Market. There is a target set in market that every marketing strategy has to reach. In addition, it also covers political and social factors which is likely to affect the growth of the market. It also covers and analysis several segments which are present in the market. A significant development has been recorded by the market of Cellular Reprogramming Tools, in past few years. It is also for it to grow further. Various important factors such as market trends, revenue growth patterns market shares and demand and supply are included in almost all the market research report for every industry.

Access Complete Report @ https://www.orbisresearch.com/reports/index/global-cellular-reprogramming-tools-market-growth-status-and-outlook-2020-2025?utm_source=Yogi

Market segment by Type, the product can be split into Segmentation by type: breakdown data from 2015 to 2020 in Section 2.3; and forecast to 2025 in section 10.7. Adult Stem Cells Human Embryonic Stem Cells Induced Pluripotent Stem Cells Other

Market segment by Application, split into Segmentation by application: breakdown data from 2015 to 2020, in Section 2.4; and forecast to 2025 in section 10.8. Drug Development Regenerative Medicine Toxicity Test Academic Research Other

One of the ways for the estimation for the growth of the market is estimation of the market share by the regions which is likely to contribute to the growth of the market in the estimated forecast period. In this, the growth and fall of each region is covered which is likely to boost the growth of the Cellular Reprogramming Tools Market. In addition, to determine and use precise methods, research methodology such as the qualitative and quantitative data is used for the estimation and determination of the Global Cellular Reprogramming Tools Market.

For Enquiry before buying report @ https://www.orbisresearch.com/contacts/enquiry-before-buying/4721627?utm_source=Yogi

About Us: Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.

Contact Us: Hector Costello Senior Manager Client Engagements 4144N Central Expressway, Suite 600, Dallas, Texas 75204, U.S.A. Phone No.: USA: +1 (972)-362-8199 | IND: +91 895 659 5155

Visit link:
Cellular Reprogramming Tools Market- By Type, Component, Industry, Region Market Size, Demand Forecasts, Company Profiles, Industry Trends and...

Investing in Life Sciences Stocks and Companies – Nanalyze

Nowhere will you find more exciting ideas to invest in than life sciences, a broad topic that encompasses around 30 different branches of study, each of which could take a lifetime to fully comprehend. As investors, we dont want to rely on subject matter experts to understand what a company does. If we cant understand a companys business, we dont want to invest in it. We also want to avoid businesses with no traction. Drug development companies with no revenues that are burning through cash trying to bring a drug to market have volatile share prices for a reason. That volatility represents uncertainty. We prefer to stick with businesses that are already selling a product or service which is generating strong revenue growth consistently. These are businesses that are leveraging life sciences technologies to achieve above-average growth.

In writing about life sciences over the past seven years, weve come across dozens of interesting life sciences companies innovating across the globe such as:

Oftentimes well find groups of startups trying to solve similar problems like creating treatments using the human microbiome or trying to cure hearing loss. Technologies like mobile health, telemedicine, and medical chatbots are democratizing access to healthcare services. Big data is helping us better treat mental health conditions while telepsychiatry now democratizes access to mental health professionals. Were now able to create bionic limbs, bionic eyes, bionic ears, bionic pancreases, and artificial hearts. Soon, we might be harvesting organs from pigs to help solve the kidney transplant problem. Robots are now performing surgeries, and it wont be long until robots are doing dental work as well. Were building labs in the cloud and organs on chips. Optogenetics lets us control cells in living tissues with light. Deep learning algorithms now discover drugs which are then administered using smart pills, smart inhalers, or even wireless drug delivery chips. Patient data is now stored using electronic medical records, data which can then be analyzed by artificial intelligence algorithms to provide things like personalized cancer treatments. When a baby is born, were able to store stem cells from cord blood and then use them for stem cell transplants later on in life. These are only the startups we know about, because many life sciences startups choose to operate in stealth mode.

Some of the problems were trying to solve are themselves emerging, such as trying to kill super bugs that stem from antibiotic resistance, or developing vaccines for new viruses like the rona. (Johnson & Johnson is pouring millions into developing a coronavirus vaccine.) Many of the problems being worked on involve cures that havent been developed yet, something we looked at in our when will there be a cure series.

Examples of innovation in life sciences abound, so weve tried to narrow it all down to six areas of focus weve been researching for investment opportunities.

Lets start with genomics.

Perhaps no field in life sciences shows more promise than that of genomics. Using genetic sequencing machines, scientists are not only able to read the recipes of life, theyre also able to edit them using technologies like gene editing. Full genome sequencing has now fallen below the $1,000 mark, and some companies now have their sites set on a $50 genome sequencing price point.

Huge databases of DNA data are now being mined for insights, and scientists are even able to reconstruct composite images of criminals form crime scenes using DNA, something referred to as DNA phenotyping.

The field of genomics is exploding as prices plummet, speeds increase, and companies continue to find new use cases. Venture capitalists are pouring money into genomics startups across the globe with China and America being seen as the current leaders in genomics. In the future, well have a world where everyone is given personalized medicine tailored to their unique genetic makeup. This is why genetic testing is becoming so popular, something well cover extensively later in this piece.

You cant talk about genomics without mentioning Illumina, a company that all but dominates the market for machines that perform gene sequencing. Weve been longtime shareholders in Illumina and added to our position back in 2016 when shares dipped to around $135 a share. As the cost of gene sequencing plummets, even more use cases are opening up for Illuminas machines leaving them plenty of room for growth. One company trying to disrupt this plan is Chinas BGI Genomics which hopes to provide an alternative for Chinese companies that dont want to use Illumina or Oxford Nanopore sequencing machines. (Oxford Nanopore is a private company that builds smaller gene sequencing devices that are less accurate.) Another publicly traded company to watch in the sequencing space is 10X Genomics which is working on single cell sequencing.

Not all genomics stocks are leaders. There are plenty of laggards, like Bionano Genomics (BNGO) which had an IPO back in 2018. The company sells instruments meant to complement next-generation sequencing machines like those sold by Illumina. Unfortunately, they couldnt grow revenues in 2019 while losses continued to increase. You cannot be in a high-growth market and not have the revenue growth to show for it.

Human longevity also referred to as life extension science involves extending the human lifespan by rolling back the effects of aging. Technologies like machine learning and genetic sequencing now mean were better able to understand the aging process. Companies like Googles Calico are analyzing millions of anonymous DNA samples in an attempt to better understand the effects of genetics on aging.Were now able to develop cellular medicines that uses live cells to repair the body.

Other companies are trying to increase the human lifespan by lengthening ones telomeres or by minimizing oxidization which causes aging. Venture capitalists are pouring money into dozens of startups tackling the aging problem in areas like regenerative medicine or young blood transfusions.

From an investors perspective, human longevity presents both risks and potential rewards as living another 20 years can have some dire effects on some peoples retirement plans. Of the top longevity companies out there, some are publicly traded. Just be aware that some companies out there are selling snake oil. Theyre preying on older people who have money and the desire to live longer. Just because someone says theyre selling anti-aging pills doesnt mean they actually work.

Weve talked before about how The Internet of Things promises to connect everything to the cloud with the byproduct being loads of big data. The same holds true in the medical industry where connected medical devices allow doctors to monitor patients vital signs from afar. Breath diagnostics devices allow us to more quickly diagnose medical conditions. Ultrasounds can now be performed with smartphones, and ultrasound technology itself is finding many other uses cases like breaking up blood clots that cause strokes. Newly developed medical devices are used to administer electroceutical therapies and wearables are helping to treat mental health.

Perhaps some of the biggest advancements are being made in medical imaging where deep learning algorithms are used to interpret medical imagery. Dozens of startups are now developing medical imaging AI algorithms to do everything from measuring breast density to preparing surgeons for surgery.

The increasing sophistication of medical devices and medical imaging algorithms mean that doctors are more easily able to treat patients from afar. Companies like Teladoc (TDOC) make it possible for anyone with $40 to speak with a doctor. For retail investors looking to invest in the telemedicine trend, Teladoc is probably the only telehealth stock to own. There are also many startups working on telehealth using technologies like machine learning to improve upon their offerings.

As we continue to develop more connected medical devices and generate more medical images, the amount of big data to analyze in healthcare is growing exponentially. Many data analytics businesses are emerging which use this data for predictive analytics or to identify inefficiencies in processes. The ability to remotely monitor patients means were able to treat more people, more effectively.

A good example of remote patient care can be found in iRhythm Technologies (IRTC). Theyve built their entire business around a medical device for remote cardiac monitoring. It comes in the form of a wearable that can capture up to two weeks of ECG data while allowing the patient to conduct their life in a perfectly normal fashion. All that data is then fed to a deep learning model capable of arrhythmia detection at a level comparable to a panel of expert cardiologists for a total of 12 output classes.

Most patient data is now stored electronically instead of being stuffed in some filing cabinet. This means a patients data can be shared across healthcare providers allowing for better care. For retail investors, there are a number of publicly traded companies working on electronic health records (EHRs) which are rapidly becoming the norm. Practice Fusion even offers EHRs for free because they know the value is in the data. Companies like Health Catalyst (HCAT) then apply healthcare data analytics to all this big data to create large-scale efficiencies.

A brain-computer interface might be the Holy Grail for human advancement. Just imagine being able to increase your brain storage capacity exponentially. And its not just about augmenting the human brain. Being able to interface with the human brain means we no longer need to use keyboards or mice. Dozens of startups are working on neurotech applications like neuroprosthetics which can rectify brain damage or neuromodulation which can be used for pain management.

Our brains contain about 2.5 petabytes (2,500,000 gigabytes) of storage, enough to store the entire contents of all US academic research libraries.Stentrodes and neural dust are just some of the methods being used to access this incredible biological data storage mechanism. Biohackers can even do this at home using technologies like OpenBCI.

If youre not familiar with the drug discovery process, its largely inefficient with billions of dollars being spent developing drugs that never actually get approved following clinical testing.

Plenty of companies are working on removing all the inefficiencies from the process. For example, a handful of startups are working on helping patients find clinical trials worldwide which they can then participate in from home. Some of the biggest advancements being made in drug discovery are the many computational drug discovery startups popping up which use machine learning to optimize the discovery process.

When drugs do get approved, some create more problems than they solve. Look no further than Americas addiction to opiates which helps explain the proliferation of startups developing substance abuse apps. Many mental health problems stem from drug abuse, so sometimes cognitive behavioral therapies are a better option than hard drugs. Some of the more severe mental health conditions like schizophrenia still arent being treated effectively which means theres still lots more work to be done.

There is no cure for cancer, theres only early detection which could make most cancers benign. Thats just one example where advancements in medical testing could prove to save lives and money, something that everyone working in medicine wants to do. Unfortunately there have been some setbacks for investors, the most notable being the implosion of Theranos. Elizabeth Crazy Eyes Holmes was behind the blood testing company which was fawned over by just about everyone. Now, shes facing criminal charges while other companies try to fill the Theranos void with their own platforms for blood testing. Some of these come in the form of mobile diagnostics platforms that can be used at the point of care.

Advances in medical testing run the gamut, from AI algorithms that detect Alzheimers to blood tests that detect cancer. Were now able to use next-generation sequencing technologies to identify genomic sequences of pathogens that are present in a patients blood or even circulating tumor cells that indicate cancer. Were even working on building the tricorder from Star Trek.

Many companies are now able to detect the presence of cancer in biofluids like blood or urine. It isnt just about early detection, its also about monitoring the progress of cancer treatments. Traditionally, a doctor would take a piece of a tumor a biopsy in order to determine if it is cancerous or benign. Now, many startups are developing liquid biopsies or blood tests that are capable of detecting cancer. One publicly traded in this space is Guardant Health (GH), an $8 billion precision oncology company that primarily sells cancer blood tests.

Once a type of cancer has been identified, we can then use next-generation sequencing to identify cancer-associated alterations thatcan be attacked usingtargeted therapies.Foundation Medicine is a leader in this space with one of the worlds largest cancer genomic databases, holding more than 400,000 genomic profiles. The company had an IPO back in 2013 and got into bed with Roche a few years later. They were finally acquired by Roche in 2018.

Across the pond we have a few publicly traded companies in this space as well. Angle (AGL:LN), a $95 million company which continues to bleed cash while generating minuscule revenues, offers liquid biopsies. Oxford Immunotec (OXFD) is having a bit better luck on the revenue side of things with their blood test for tuberculosis.

Apocell used to be publicly traded but has since been taken private. Theres also a Japanese firm called Sysmex (6869:JP) which is the global market leader inhematology,occupying the number-oneshare of theworldwide market. They have a subsidiary called Sysmex Inostics which has developed an ultra-sensitivedigital PCR technologythat is capable of detecting cancer cell DNA directly from blood.

Blood isnt the only bodily byproduct used to detect cancer. A $13 billion company called Exact Sciences (EXAS) sells a stool DNA test for colorectal cancer. Exosome Diagnostics acquired by Bio-Techne is developing a urine test for prostate cancer. All these samples flying around mean that entire businesses are now being built around the storage and transportation of biological samples.

There are also companies developing cancer therapies that are fine-tuned to certain genomic profiles like personalized chemotherapy. This is where some genetics testing comes in handy.

To say that genetic testing has exploded is an understatement. There are now genetic tests for nearly everything, including genetics tests for pets. In looking at some of these testing use cases, they seem to be borderline gimmicks like DNA dating or genetic fitness tests. Others provoke a great deal of controversy, like genetic tests for intelligence. There are now DNA apps for nearly everything, but where it all started was with ancestry genetic tests.

Large ancestry testing companies like 23andMe and Ancestry.com quickly realized that the real value to be had was not in selling genetic tests, but collecting genetic data and monetizing it. This quickly led to privacy concerns around genetic data. As more and more companies started offering genetic testing services, the big providers started to pivot into genetic healthcare tests for hereditary diseases like cancer or heart disease. Soon, this started to attract the attention of regulatory authorities. Telling someone their dad isnt their dad isnt nearly as painful as mistakenly getting a double mastectomy because a genetic test said you were at risk for breast cancer. Youd be surprised to see how many ancestral differences you get when you run the same DNA sample through multiple test providers. (This is why Family Tree DNA offers a central DNA results database where you can upload all your test results.) When it comes to health related genetics testing, accuracy is paramount.

The evolution of genetics testing is now leading to new business models that try to adapt to the environment. Nebula now offers anonymous DNA testing. Centogene is building the worlds largest repository for genetic information on rare hereditary diseases in the world. Were learning more about how polygenic risk scores can help predict disease. Being able to interpret genetic data is becoming much easier thanks to technologies like machine learning. Even with all these new technologies, theres still an important human element to the whole thing. Finding out that youre at risk for hereditary cancer isnt all that useful unless someone tells you exactly what that means and what steps you should take if any.

For retail investors, theres one pure-play genetic testing stock you ought to consider which just expanded into personalized oncology with their acquisition of ArcherDX Invitae (NVTA). Since we first came across the company seven years ago, theyve come a long way.

Some other themes weve looked at manifest themselves over time as we notice their prevalence. For example, who knew that diabetes would be such a big industry.

All these people who talk about how big is beautiful need to realize that its just not. Sure, there are some cultures that glorify obesity because it represents wealth and security. In America, fat asses abound because people drive up to windows to consume two days of calories in one seating which they then wash down with a diet soda.

The hard truth is that obesity is unhealthy and a contributing factor to a huge global problem diabetes. Weve talked before about why there isnt a cure for diabetes yet. Until there is, we need to treat the more than 100 million U.S. adults who are now living with diabetes or prediabetes.

All kinds of companies are working on diabetes treatments. Dance Biopharm (now Aerami Therapeutics) is working on an inhaled insulin product. Intarcia Therapeutics is working on a potential once-a-year diabetes treatment. But no matter how compelling these products sound, there will be failures, like Cellnovos attempt at developing insulin pumps. Kind of hard to compete with Medtronic (MDT), one of the worlds biggest medical device makers, which already has that sorted with a digital form of an artificial pancreas. (Full disclosure: were long-time shareholders in MDT for dividend growth reasons.)

Another theme we looked at for a bit was non invasive prenatal testing (NIPT) which is pretty much what it says on the tin. Its a test that makes sure your little bundle of joy doesnt pop out with two heads, or be afflicted by any malady that would interfere with the perfect life youve planned for it. Plenty of companies are dabbling in this space, like Ariosa Diagnostics which was acquired by Roche since we last looked at them. Other publicly traded stocks in this space include Natera (NTRA) and Premaitha Health (YGEN:LN) which now goes under the name Yourgene.

We stopped looking at NIPT because we believed the NIPT growth story might be ending. We also didnt find the topic to be that interesting frankly unless of course they come out with a NIPT for intelligence which wed probably invest in.

Stem cells are kind of like a foundation cell that various types of other cells get built on like muscle cells or brain cells. These are useful for applications like regenerating body parts or figuring out what makes cancer cells replicate. One company we looked at, Cellular Dynamics, was in the business of producing stem cells. Theyve since been acquired by Fujifilm Holdings. Another company we looked at was Fate Therapeutics (FATE) which uses renewable master induced pluripotent stem cell (iPSC) lines to produce cellular immunotherapies. We have no idea what that actually means, which is why were not investors in the company. We only like to invest in businesses we can easily understand.

Over the years of developing our life sciences topics, we encountered quite a few companies that we just didnt fully understand. Roivant Sciences was one of them. So were the nant companies coming from the brain of Dr. Soon Shiong, one of the worlds most successful biotech investors. Its very difficult to understand some of these businesses without having a medical background, and if you need eight years of training to understand what a company does, its probably too complex for retail investors. Weve given up on trying to figure out how Nanthealth will revolutionize the U.S. healthcare system, or what Nantkwest does, and instead stick to companies with business models anyone can understand. Another area of life sciences weve looked into before but decided not to follow is RNAi therapeutics.

Another area we looked at briefly was RNAi therapeutics and publicly-traded RNAi companies like Benitec, Dicerna Pharmaceuticals, or Moderna which has soared after going public due to their work on a coronavirus vaccine. To this day, we still dont feel like we sufficiently understand what many of these companies do which means were not able to properly explain them to our readers. Instead of spending hours trying to understand how microRNA relates to RNAi, were staying away from drug development companies entirely. Even if a company has the greatest drug development platform in the world, theres always a risk theyll fail given all the pitfalls of drug development we discussed earlier. The exception to that rule might be the drug development arm of Johnson & Johnson, a company we hold as part of our dividend growth investing strategy.

Fields like cancer immunotherapy, cancer stem cell research, or epigenetics may have loads of promise, but most of these investments are just too complex for your average Joe investor to understand without having an interpreter. Lets talk about some stocks that you dont need an interpreter to understand.

Given the breadth of technologies to be found under life sciences we often take fleeting looks at companies that are doing cool things without necessarily doing any deep-dives or follow ups. These one-offs are oftentimes stocks or planned IPOs we come across that we think our readers might find interesting.

One thing all these stocks have in common is that theyre traded on major exchanges unlike penny stocks which you should avoid like the plague.

We never skip a chance to warn investors about the dangers to be found when dabbling in penny stocks (also called over-the-counter (OTC) stocks). Here are just some of the OTC companies weve written about.

Investing in any these companies would have proved to be a total disaster. Of course there are always some exceptions, but why try to walk through landmines to find them? Do not speculate on penny stocks, no matter how compelling their story is.

Oftentimes well come across micro-cap stocks on foreign exchanges which well write about. More often than not, these companies will end up going nowhere fast. Kiwi company Adherium (ADR:AU) was supposed to bring us intelligent inhalers. While investors continue to wait, their share price continues to plummet. We warned investors that Canadian firm BioMark Diagnostics (BUX:CN) might not have what it takes to bring cancer blood tests to market, and the company still appears to be going nowhere fast. Londons Tissue Regenix (TRX:LN) was working on some exciting new skin scaffolds, but you would have lost -90% of your investment waiting for them to finally start achieving some traction. Even though revenues are picking up and losses are trending in the right direction, shares continue their long downward slide. Its best not to try and catch a falling knife.

Some readers may wonder why we havent touched on one of the most exciting technology there is synthetic biology. Thats because weve dedicated an entire page to synthetic biology, our Guide to Investing in Synthetic Biology. The same holds true for gene editing, something we covered in our Guide to Investing in Gene Editing Stocks. We happen to classify gene editing and synthetic biology under our nanotechnology category, so you may want to go read our Guide to Investing in Nanotechnology Stocks and Companies next. Because life sciences is such a broad category, youll find it peppered throughout all the twelve categories of disruptive technologies we cover here at Nanalyze. For example, machine learning algorithms are now helping us understand extremely complex things such as the human microbiome.

Sure, you can cure your STDs without going to a doctor, but developing something as simple as a universal flu vaccine is still out of reach. While plenty of progress is being made in life sciences, there are still plenty of diseases we cant cure and problems we cant solve. Its safe to say that investors will continue to reap rewards by investing in life sciences companies for decades to come.

Interested in hearing more about investing in life sciences companies and stocks?Sign up for our weekly newsletter. Well keep you up-to-date on life sciences investments and all the disruptive technologies out there that ought to be on investors radar. No politics, no B.S., no corporate buzzword bingo.Click here to sign up for Nanalyze Weekly.

Follow this link:
Investing in Life Sciences Stocks and Companies - Nanalyze

Blood Test Could Reveal When Rheumatoid Arthritis Will Strike – Howard Hughes Medical Institute

Scientists have identified a new type of cell that appears in the bloodstream of rheumatoid arthritis patients shortly before joint inflammation flares.

A never-before-seen cell type could forewarn of rheumatoid arthritis symptoms.

The cells, dubbed PRIME cells, accumulate in the blood during the week prior to disease flare-ups, Howard Hughes Medical Institute Investigator Robert Darnell's team reports July 15, 2020, in the New England Journal of Medicine. The findings could lead to better prediction of when severe pain and swelling, called flares will occur, as well as provide new avenues for treatment.

PRIME cells are one thing you might want to target to arrest the flare before it happens, Darnell says. Thats the ideal of medical science to know enough about a disease that you can put your finger on whats about to make someone sick.

Rheumatoid arthritis is a disease of the immune system that causes inflammation in the joints, especially around the hands and feet. It can be debilitating and frequently strikes people in their 30s or 40s. The symptoms come in waves, with stretches of relative quiet interspersed with painful flares. Current therapeutics, chiefly steroids, can treat these symptoms, but theres no cure.

To study this sort of disease, where symptoms vary dramatically from week to week, its critical to track changes in the body over an extended time. But its hard for patients to trek to a clinic for frequent testing. So Darnell, a neuro-oncologist at the Rockefeller University, and his colleagues developed an at-home blood collection system. Patients with rheumatoid arthritis did simple finger sticks and sent their blood to his lab. Each participant also kept a record of symptoms to identify when flares occurred.

PRIME cells are one thing you might want to target to arrest the flare before it happens.

Robert Darnell, HHMI Investigator at The Rockefeller University

Armed with these records, the researchers tested the blood samples, looking for molecular changes preceding the onset of symptoms. By analyzing the RNA of cells in the bloodstream, Darnells team could identify which types of cells were present during symptom-free times and in the weeks preceding a flare.

In samples collected two weeks prior to a flare, researchers saw an increase in immune cells called B cells. Thats not surprising, Darnell says researchers already knew these cells attacked patients joints in rheumatoid arthritis.

But in samples collected one week before a flare, his team noticed something odd. They saw an increase in RNA that didnt match the genetic signature of any known type of blood or immune cell. That got us thinking there was something fishy going on, says study coauthor Dana Orange, a rheumatologist at Rockefeller. The RNA signature instead resembled that of bone, cartilage, or muscle cells cells not typically found in the blood.

Darnells team called the newfound cell type a PRIME cell, for pre-inflammation mesenchymal cell. (Mesenchymal cells are a type of stem cell that can develop into bone or cartilage.) In the patients, PRIME cells accumulated in the bloodstream a week before the flare but disappeared during the flare. This observation, combined with previous work from another lab in mice, suggests a possible role for PRIME cells in rheumatoid arthritis flares, Darnell says.

One of the teams next steps is to test in more patients whether the presence of these cells can predict a flare, Darnell says. The researchers are still recruiting patients for this study; currently the teams blood collection system is only available for use in research. Darnell also wants to study PRIME cells molecular characteristics. If the cells do indeed take part in causing flares, he says, understanding the unique aspects of PRIME cells might enable us to target them with a drug and get rid of them.

###

Citation

Dana E. Orange et al. RNA Identification of PRIME Cells Predicting Rheumatoid Arthritis Flares, New England Journal of Medicine. Published online July 15, 2020. doi: 10.1056/NEJMoa2004114

More:
Blood Test Could Reveal When Rheumatoid Arthritis Will Strike - Howard Hughes Medical Institute

U of T spin-off Empirica Therapeutics acquired by US firm – News@UofT

Empirica Therapeutics, a startup co-founded by Donnelly Centre investigatorJason Moffathas beenacquired by Century Therapeutics, a U.S. based company developing off-the-shelf cell therapy products for cancer.

Century will develop Empiricas proof-of-principle treatment for glioblastoma, an aggressive form of brain cancer, into therapy that can be tested on patients.

Moffat co-founded Empirica in 2018 with Dr. Sheila Singh, professor in the department of surgery at McMaster University, to leverage their combined expertise in cell engineering, functional genomics and brain tumour modelling. The teams recently demonstrated the potential of CAR-T cell therapy, in which immune cells are instructed to kill tumour cells, for the treatment of glioblastoma in preclinical models, as published in a May 2020Cell Stem Cellpaper.

Recent advances in immunotherapy have offered hope to patients with previously untreatable cancers, says Moffat, a professor of molecular genetics at U of T and the Canada Research Chair in Functional Genomics of Cancer who served as Empiricas chief scientific officer. We hope that our approach of specifically targeting glioblastoma cells with CAR-T therapy will give the patients a better quality of life and increase their chances of survival.

Philadelphia-based Century Therapeutics will further develop this type of treatment for patients. Backed by Bayer, Fujifilm, and Versant Ventures, the company specializes in developing cell therapies from induced pluripotent stem cells (iPSCs) that have been genetically engineered to avoid immune rejection. Century is working to harness the power of stem cells to develop curative cell therapy products for cancer that overcome the limitations of first-generation cell therapies. The companys CEO, Lalo Flores, acknowledged Empiricas deep expertise and unique capabilities that will accelerate their efforts to develop iPSC derived immune effector cell products designed to treat brain cancer.

Chimeric antigen receptor T cell (CAR-T) therapy involves genetically engineering a patients immune T cells to target and bind to a specific protein present on cancer cells directly and eliminate them. Centurys technology skirts the need to collect patients own immune cells thanks to its ability to manufacture off-the-shelf T cells that can be implanted without rejection.

Our team is excited to become part of Century Therapeutics, whose iPSC-derived allogeneic cell therapy platform is creating promising treatments for patients who need them most, says Dr. Singh, who is also a Canada Research Chair in Human Cancer Stem Cell Biology and served as Empiricas chief executive officer.

Now known as Century Therapeutics Canada, the new subsidiary will be based at McMaster Innovation Park.

Empiricas first CAR-T program was focused on a protein called CD133, which was the first brain tumor initiating cell marker discovered by Singh while a PhD student at the University of Toronto. Subsequent work by both the Singh and Moffat groups led to a deeper functional understanding of CD133 and an antibody that proved useful for marking cells for therapy.

When used in mice with human glioblastoma, CD133-targetting CAR-T therapy was considered a success due to reduced tumor burden and improved survival. These pre-clinical results were partly supported by a Terry Fox Research Institute New Frontiers Program Project Grant awarded to a multidisciplinary team of scientists including Singh and Moffat.

Glioblastoma is the most common and aggressive form of brain cancer owing to tumour heterogeneity at the molecular level and its ability to evolve into new forms that resist therapy. Standard treatment involves surgery, radiation and chemotherapy but most patients relapse within seven to nine months, while median survival between diagnosis and death has not extended beyond 16-20 months over the past decade.

CAR-T will be delivered in recurrent glioblastoma patients after Moffat and Singhs teams found that a population of CD133 positive glioblastoma cells remain following initial treatment.

If we can hit those cells at minimal disease, we should buy the patient more time, says Moffat. And hopefully well find a way to figure out how to combine multiple CAR-Ts; for example, by combining CD133 and other targets to potentially even cure the disease.

Empirica Therapeutics was supported by investments from U of Ts strategic partners, the Centre for Commercialization of Antibodies and Biologics and the Centre for Commercialization of Regenerative Medicine.

We are proud to have been involved with the launch and growth of Empirica, stated Rob Verhagen, former CEO of CCAB. The outcome with Century marks another stride in building a productive life science industry at U of T and McMaster and we look forward to seeing this valuable research benefiting patients in the future. The startup was also supported by the McMaster Industry Liaison Office and the Ontario Bioscience Innovation Organization through important connections to relevant business networks and partners.

Read the original:
U of T spin-off Empirica Therapeutics acquired by US firm - News@UofT

Video: The Science Of Cannabis And CBD With Four Leading Experts – Benzinga

While there is mounting anecdotal evidence on the therapeutic benefits of cannabis and CBD, including their anti-inflammatory and anxiolytic effects, we still dont fully understand the underlying biological mechanisms leading to their efficacy, or why they can be effective for some people, but not for others.

Groundbreaking new human studies from UC San Diego, University of Utah, and the Wholistic Research and Education Foundationare about to change all that:

Watch the expert panel put together by Trailblazers, moderated by Benzinga Cannabis Managing Director and El Planteo CEO Javier Hasse, to learn about the cutting edge, multidisciplinary studies underway to explore just how cannabis and CBD deliver their diverse health benefits.

Photo: Pelin Thorogood announcing the Trailblazers Partnership with Wholistic Foundation August 18, 2019 with , Dr. Jeff Chen , Dr. Jeff Anderson, and Tyler Wakstein.

2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

The rest is here:
Video: The Science Of Cannabis And CBD With Four Leading Experts - Benzinga

Pressing ahead – PharmaTimes

3D bioprinting pushes the boundsof human tissue engineering

From aerospace components to complete building structures, 3D printing technologies are at the forefront of innovation across a range of industries. The possibilities in flexible design, accuracy and personalisation are also being grasped in bionics with the manufacture of prosthetic hands and limbs.

Yet the human applications of advanced manufacturing are even more fundamental when the ink in the 3D printer is literally the stuff of life. Using biological materials such as human cells, the advancing technology of 3D bioprinting is generating great interest, investment and hope. The applications and benefits are significant and wide-ranging. 3D bioprinting is pushing the boundaries of tissue engineering, with huge gains in time, efficiency, precision and reproducibility. Reducing the need for animal testing, 3D-bioprinted tissues can also raise the success rate of new drugs in clinical trials, cutting the exorbitant cost and long lead times for development. In the longer term, fully functional human organs could be bioprinted, saving lives by bypassing transplant waiting lists and pre-empting rejection with a perfect match to each patients unique physiology.

What is 3D bioprinting?

A technological breakthrough amid many 3D printing (3-DP) technologies, bioprinting is not always clearly defined or understood.

The European Parliament defines 3D bioprinting broadly as the use of 3D printing technology for applications related to the body, whether the products themselves include biological material or not, and whether or not their purpose is medical. It includes any application for rehabilitating, supporting or augmenting any kind of biological functionality.

The US Food and Drug Administration (FDA) does not have an official definition, but regularly uses the term 3D bioprinting to refer to the use of biological materials. Canadas Agency for Drugs and Technologies in Health (CADTH) makes the distinction between 3-DP techniques that manufacture biocompatible materials such as implants or prosthetics and 3D bioprinting as a 3-DP technique that uses biological materials such as human cells.

It is this narrower sense and a 3D-P sector that is undergoing a surge of interest that is the focus here.

How it works

3D bioprinting fabricates tissues from biological materials such as human and animal cells and collagen. Stem cells have the advantage of being able to adapt to host tissues and create an organ-like tissue or organoid, a model resembling a mini-organ. The bioprinting occurs inside a bioreactor, which maintains a sterile environment to avoid contamination. Specific temperatures and humidity conditions are also necessary for the cells to stay alive. To produce the bioink used for bioprinting the tissue, cells are collected from patient biopsies and are maintained in culture. Once sufficient cells are generated they are loaded into a cartridge and the bioprinting can start.

Pharma companies see immense potential in 3D bioprinting technology, especially for development of drugs and cosmetics. MSD, for example, entered into an agreement with the bioprinting pioneer Organovo back in 2015 to gain commercial access to its latest 3D-bioprinted human liver tissue for toxicology and pre-clinical drug testing.

Last year chemicals giant BASF joined forces with CTI Biotech to develop a new 3D-bioprinted skin for cosmetic testing. The skin tissue produced by the French specialist in regenerative medicine incorporates immune cells, which are essential for studying the anti-inflammatory properties of active cosmetic ingredients. The collaboration has proved successful, demonstrating major bioprinting capabilities by fabricating a substantial number of skin model copies in a relatively short time. The overarching aim is to accelerate development of innovative and highly reliable ingredients for the huge skincare market.

This prospect of significant time (and cost) savings is one the main advantages the technology offers. The other factor spurring the growing interest of pharmaceutical and chemical groups is the ability to generate complex structures, opening the door to bioartificial tissues and advanced therapies.

Timely production

A tremendous time-saving can be achieved with 3D bioprinting. Scientists in Madrid succeeded in bioprinting a tissue resembling human skin using cells from patient biopsies in just 35 minutes. The same amount of skin-like tissue, which can be used for treating burns and wounds, previously required three weeks of manual fabrication. No decline in the quality of the tissue was observed, in fact, thorough analysis showed that it was not possible to distinguish between the bioprinted and manually produced tissues.

This combination of speed and quality control means the production process can be more easily scaled up. CTI Biotech which produces 3D human tissue models for cancer research as well as dermatology has recently invested 600,000 euros in the acquisition of five bioprinters from Cellink, the Swedish developer of the Bio X printer. These bioprinters are used to produce micro-tumours in the search for new cancer treatments. They have three printheads, with cartridges dedicated to cancer cells (from patients), fibroblasts and immune cells. The bioprinter is programmed to reproduce a replica tumour to a computer design. Previously, lab assistants had to deposit a liquid containing cells drop by drop in a long, tedious process. Now its bioprinting facility can produce hundreds of micro-tumours in a matter of minutes.

Such productivity promises the potential to automate tissue engineering and ramp-up production.

Reproducing complexity

As well as streamlining production, bioprinting technology ensures the reproducibility of the process, eliminating the significant variations arising from manual methods, so the tumours are identical. This means they reproduce with more accuracy the natural environment experienced by cells in the living organism.

In the cancer example, researchers create CAD designs that map the complex morphology of tumours and cell structures with high precision. Using bioprinting software, the production process is capable of creating even highly complex 3D tissues with high reproducibility.

When accurately reproduced, cell arrangements allow a significantly higher connection between different types of cells to mimic human tissue reactions. This creates the potential for identifying the toxicity and effectiveness of new medications much earlier in the drug development process.

Compared with manually produced 3D tissues which have severe limitations in terms of lack of control over size, low reproducibility, and level of complexity bioprinted models can have a far higher impact on the success rate of clinical trials.

There are other drivers behind the investment in 3D bioprinting.

The cosmetic industry began to engage with the technology in the face of legislation prohibiting animal testing. The European Unions first ban covered finished products in 2004, followed by cosmetic ingredients in 2009. A complete ban on production and marketing of products tested on animals took effect in 2013. This has accelerated the development of human-based 3D skin tissues for cosmetic ingredient testing, and statutory bans on animal testing have followed in many other jurisdictions around the world. As bioprinting of this relatively simple form of tissue has become highly advanced, so has bioink and the ability to print more complex structures with different types of cells.

Drug development

Animal testing, however, is still authorised and required for the development of new drugs, and often used for preclinical validation. As well as being highly controversial, the testing of formulations on animals is also one of the reasons blamed for the low success rate of clinical trials. On average, only 10% of drugs that reach clinical stage development obtain FDA approval and are commercialised. Because animal and humans have very different physiologies, a drug that shows promising results in an animal will not necessarily be effective in a person. For the other 90% of drugs, it is estimated that the cost of each failure ranges from $800 million to $1.4 billion. Mitigating this risk and reducing costs is a huge incentive for pharmaceutical companies to develop and exploit bioprinting solutions.

In the case of CTI Biotech, it expects its investment in bioprinting micro-tumours to halve the time taken to develop new medicines to three years and decrease its cost by 20%. Such potential translates into high market values.

Organovo whose bioprinted liver tissues are being used for preclinical toxicology validation values the current market for liver and kidney in vivo tissue testing at close to $3 billion. As bioprinting proves to be a cost-effective and efficient solution in other areas, the value of the technology can only grow.

A 2017 research report projected that 3D bioprinting applications would be generating $1 billion in revenue annually within a decade. Drug discovery and cosmetics testing would account for most of this market, but tissue regeneration could become an even larger opportunity beyond 2027. It was followed, in autumn 2018, by a bullish projection that the global bioprinting market including 3D bioprinting machines, bioink, consumables, software and related services would be worth $4.7 billion by 2025.

As 3D bioprinting proves to be a cost-effective and efficient technology for producing tissue samples in an ethical manner, R&D investment is growing. In 2019, the European Union granted funding to 13 bioprinting research projects, worth a total of 28 million euros.

Where next?

Some scientists estimate that it will be possible to bioprint full-sized and fully functional organs within the next ten years. Not all of the scientific community agrees with this timeline. Given the astounding complexity of organs and their complicated networks of veins and capillaries, the challenges cannot be underestimated. Nerves, blood vessels and lymphatic vessels must not only be incorporated, but also integrated with the bodys other systems.

This goes considerably beyond bioprinting and transplanting skin, bone and other body components such as an ear, trachea or cardiac valve, which is already feasible. It may be that, at least in the medium term, bioprinting remedial patches of tissue yields more reliable and valuable results, perhaps in combination with other regenerative treatments, repairing rather than replacing diseased organs.

Organovo has shown how human liver tissue 3D-printed with the necessary variety of cell types functions and engrafts when implanted in small animal disease models for up to 90 days. It sees the immediate challenge as increasing the size of grown tissue for paediatric patients and small adults.

The ultimate goal for champions of the technology is organ replacement. Expanding the boundaries of 3D tissue engineering to the point of producing sophisticated tissues and organs for patients awaiting transplants would transform and save lives. Bioprinted transplantable organs using patients own cells would overcome the challenges of immunosuppression and rejection.

The human need is near limitless, given a global shortage of organs for lifesaving transplants. In the US the lack of donor organs is the leading cause of death. In the UK patients wait an average of two-and-a-half years for a kidney transplant, with similar shortages for liver, lungs and other organs.

Perfecting the production of implantable organs is a formidable challenge requiring significant investment and research breakthroughs in bioink and 3D bioprinting, while integrating technologies in biomaterials science, cell biology, physics and medicine. If successful, the high costs of the technology would limit the impact on waiting lists, even though more cost-effective bioprinters using 3D printer components are becoming available.The prospect of decentralised bioprinting of personalised implants to order in local hospitals and clinics remains, for now at least, in the realm of science fiction.

Bioprinting advances

Yet innovations in bioink and bioprinting techniques are emerging that lend some credence to optimistic predictions for bioprinting.

Scientists in the US have developed a novel method to bioprint functional parts of a human heart, such as valves and ventricles. Tissue scaffolds are fabricated from collagen, the major structural protein in the human body. Based on an MRI scan, the anatomical structure of a patients heart can be replicated with high precision. Their method also allows transmission of biochemical signals between the bioprinted heart cells, crucial for the organs normal functioning within a living body. The technique is seen as a step closer to bioprinting a full-sized, viable adult human heart.

In Brazil scientists have succeeded in bioprinting a fully functional mini-liver that is able to store vitamins and provide vital body functions. Combining several bioengineering techniques, their innovative bioink used clumps of cells to maximise contact between them and maintained tissue functionality for much longer than in other studies. The mini-organ was bioprinted in 90 days using a patients blood cells.

A joint team of researchers in France and the Netherlands claimed in summer 2019 that their volumetric bioprinting technique was a game-changer for tissue engineering. They projected a laser down a spinning tube of hydrogel laden with stem cells. Focusing the energy creates complex 3D shapes in a few seconds. Introducing endothelial cells (from lymphatic and blood vessels) makes the tissue vascular. A heart valve, meniscus and complex-shaped part of the femur were produced.

Another bioprinting avenue of development, which GE Healthcare is pursuing, is 4D bioprinting. This would mean printing of 3D tissues with the capability to respond over time to their environment and change in shape (eg growing) or function (eg cellular differentiation or even organ development). Frances Poietis is developing a 4D bioprinting approach using single-cell resolution, artificial intelligence and software designed to programme tissue self-organisation so it matures in a controlled way until biological functions emerge.

Personalisation of medicine on the back of advances in gene therapy is also expected to reinforce interest in custom-building tissues and organs from patients own cells and ongoing innovation in this field.

As on other new frontiers of medicine, there will be safety, ethical and regulatory controls to navigate.

There is currently no overarching regulatory regime governing the whole bioprinting process, but various pieces of legislation apply to tissue engineering and regenerative medicine (such as the European Commissions Regulation on Advanced Therapy Medicinal Products). In the UK, the Parliamentary Office of Science and Technology (POST) has started to take a close interest. A POSTnote due during 2020 will give parliamentarians advance knowledge of the public policy issues and pay specific attention to quality management in what would be decentralised manufacturing.

Development of bioprinting could be affected by disallowing certain bioinks or techniques. Contrariwise, clarification from regulatory agencies around safety and efficacy could help clear the way for clinical trials.

The legislative framework on bioprinting is sure to evolve in coming years. The only question is the pace, and to what extent this will lag or be dictated by developments in the field.

Delphine Malard is associate consultant at Ayming

Follow this link:
Pressing ahead - PharmaTimes

New Study Finds Novel Hyperbaric Oxygen Therapy Protocol Can Improve Cognitive Function of Healthy Older Adults – PRNewswire

TEL AVIV, Israel, July 15, 2020 /PRNewswire/ -- The Sagol Center for Hyperbaric Medicine and Researchat Shamir Medical Center, and Tel Aviv University today announced that, for the first time in humans, a peer-reviewed study has demonstrated that hyperbaric oxygen therapy (HBOT) can significantly enhance the cognitive performance of healthy older adults.

The main areas of improvement were attention, information processing speed and executive function, in addition to global cognitive function, all of which typically decline with age. Moreover, there was a significant correlation between the cognitive changes and improved cerebral blood flow in specific brain locations.

The study was published on July 15, 2020 in the peer reviewed journal Aging, entitled: Cognitive enhancement of healthy older adults using hyperbaric oxygen: a randomized controlled trial.

Professor Shai Efrati and Dr. Amir Hadanny designed the study based on a unique HBOT protocol developed at the Sagol Center over the past 10 years. The randomized controlled clinical trial included 63 healthy adults (>64) who underwent either HBOT(n=33) or a control period (n=30) for three months. The study's primary endpoint included a change in general cognitive function measured by a standardized comprehensive battery of computerized cognitive assessments before and after the intervention or control. Cerebral blood flow (CBF) was evaluated by a novel magnetic resonance imaging technique for brain perfusion.

"Age-related cognitive and functional decline has become a significant concern in the Western world. Major research efforts around the world are focused on improving cognitive performance of the so-called 'normal' aging population," said Prof. Efrati, Director of the Sagol Center for Hyperbaric Medicine and Research. "In our study, for the first time in humans, we have found an effective and safe medical intervention that can address this unwanted consequence of our age-related deterioration."

"Over years of research, we have developed an advanced understanding of HBOT's ability to restore brain function. In the past, we demonstrated HBOT's potential to improve/treat brain injuries such as stroke, traumatic brain injury and anoxic brain injury (due to sustained lack of oxygen supply) by increasing brain blood flow and metabolism," explained Amir Hadanny, MDS, Chief Medical Research Officer of TheSagol Center for Hyperbaric Medicine and Research and author of the aging study. "This landmark research could have a far-reaching impact on the way we view the aging process and the ability to treat its symptoms."

During HBOT, the patient breaths in pure oxygen in a pressurized chamber where the air pressure is increased to twice that of normal air. This process increases oxygen solubility in the blood that travels throughout the body. The added oxygen stimulates the release of growth factors and stem cells, which promote healing. HBOT has been applied worldwide mostly to treat chronic non-healing wounds.

There is a growing body of evidence on the regenerative effects of HBOT. Sagol Center researchers have demonstrated that the combined action of delivering high levels of oxygen (hyperoxia) and pressure (hyperbaric environment), leads to significant improvement in tissue oxygenation while targeting both oxygen and pressure sensitive genes, resulting in restored and enhanced tissue metabolism. Moreover, these targeted genes induce stem cell proliferation, reduce inflammation and induce generation of new blood vessels and tissue repair mechanisms.

"The occlusion of small blood vessels, similar to the occlusions which may develop in the pipes of an 'aging' home, is a dominant element in the human aging process. This led us to speculate that HBOT may affect brain performance of the aging population," Prof. Efrati explained. "We found that HBOT induced a significant increase in brain blood flow, which correlated with cognitive improvement, confirming our theory. One can conjecture that similar beneficial effects of HBOT can be induced in other organs of the aging body. These will be investigated in our upcoming research."

The research group leader, Professor Shai Efrati, who serves as Director of The Sagol Center for Hyperbaric Medicine and Research, also disclosed his role with Aviv Scientific LTD, which has developed a comprehensive program that includes HBOT treatment, cognitive and physical training and nutritional coaching, to enhance brain and body performance of aging adults based on the Sagol HBOT protocol at Aviv Clinics. Prof. Efrati serves as Chair of Aviv Scientific's Medical Advisory Board.

About the Sagol Center for Hyperbaric Medicine and Research

The Sagol Center for Hyperbaric Medicine and Research at Shamir Medical Center (formerly Assaf Harofeh Medical Center), is a global leader in advancing the understanding of the impact of hyperbaric medicine on cognitive and physical function. Serving as one of the largest Hyperbaric centers worldwide, the Sagol Center offers highly advanced large multiplace chambers, treating more than 200 patients daily. Research conducted at the Center has proven that brain rejuvenation is possible across a wide range of neurological pathologies and illnesses.

Media Contact:

Nicole Grubner Finn Partners for The Sagol Center for Hyperbaric Medicine and Research +1-929-222-8011 [emailprotected]

SOURCE The Sagol Center for Hyperbaric Medicine and Research

https://www.shamir.org/en/unique-pages-default-aspx/the-sagol-center-for-hyperbaric-medicine-and-research/

Originally posted here:
New Study Finds Novel Hyperbaric Oxygen Therapy Protocol Can Improve Cognitive Function of Healthy Older Adults - PRNewswire

Global Stem Cell Assay Market Growth is Projected to Grow at Sluggish Rate by 2027 Post COVID 19 Pandemic Merck, Thermo Fisher Scientific, GE…

Stem Cell Assay Market report involves all together a different chapter on COVID 19 Impact. The Covid-19 (coronavirus) pandemic is impacting society and the overall economy across the world. The impact of this pandemic is growing day by day as well as affecting the supply chain. The COVID-19 crisis is creating uncertainty in the stock market, massive slowing of supply chain, falling business confidence, and increasing panic among the customer segments. The overall effect of the pandemic is impacting the production process of several industries including Life Science, and many more. Trade barriers are further restraining the demand- supply outlook. nicolas.shaw@cognitivemarketresearch.com or call us on +1-312-376-8303. Download The report Copy form the webstie: https://cognitivemarketresearch.com/medical-devicesconsumables/stem-cell-assay-market-report

The major players profiled in this report include: Merck, Thermo Fisher Scientific, GE Healthcare, Agilent Technologies, Bio Rad Laboratories, Promega, Cell Biolabs, PerkinElmer, Miltenyi Biotec, HemoGenix, Bio Techne, STEMCELL

Market segment by type can be split into: Viability, Purification, Identification

Market segment by the application can be split into: Regenerative Medicine, Clinical Research

DOWNLOAD FREE SAMPLE REPORT@: https://cognitivemarketresearch.com/medical-devicesconsumables/stem-cell-assay-market-report#download_report

As government of different regions have already announced total lockdown and temporarily shutdown of industries, the overall production process being adversely affected; thus, hinder the overall Stem Cell Assay globally. This report on Stem Cell Assay provides the analysis on impact on Covid-19 on various business segments and country markets. The report also showcases market trends and forecast to 2027, factoring the impact of COVID-19 situation.

Stem Cell Assay Market report provide an in-depth understanding of the cutting-edge competitive analysis of the emerging market trends along with the drivers, restraints, and opportunities in the market to offer worthwhile insights and current scenario for making right decision. The report covers the prominent players in the market with detailed SWOT analysis, financial overview, and key developments of last three years. Moreover, the report also offers a 360 outlook of the market through the competitive landscape of the global industry player and helps the companies to garner Stem Cell Assay Market revenue by understanding the strategic growth approaches.

Any query? Enquire Here For Discount (COVID-19 Impact Analysis Updated Sample): Click Here> Download Sample Report of Stem Cell Assay Market Report 2020 (Coronavirus Impact Analysis on Stem Cell Assay Market)

Report provides industry analysis, important insights, and a competitive and useful advantage to the pursuers. The report analyzes different segments and offers the current and future prospects of each segment. Furthermore, this research report contains an in depth analysis of the top players with data such as product specification, company profiles and product picture, sales area, and base of manufacturing in the global Stem Cell Assay market. The impact on the supply and demand of the raw materials, due to the COVID-19 is also analyzed in the global Stem Cell Assay market.

Additionally, report consists of product life cycle, which discus about the current stage of product. Further, it adds manufacturing cost analysis as well as complete manufacturing process involved. Report also adds supply chain analysis to ensure complete data of market.

Objectives of Stem Cell Assay Market Report: To justifiably share in-depth info regarding the decisive elements impacting the increase of industry (growth capacity, chances, drivers and industry specific challenge and risks) To know the Stem Cell Assay Market by pinpointing its many sub segments To profile the important players and analyze their growth plans To endeavor the amount and value of the Stem Cell Assay Market sub-markets, depending on key regions (various vital states) To analyze the Global Stem Cell Assay Market concerning growth trends, prospects and also their participation in the entire sector To inspect and study the Global Stem Cell Assay Market size form the company, essential regions/countries, products and applications, background information and also predictions to 2027 Primary worldwide Stem Cell Assay Market manufacturing companies, to specify, clarify and analyze the product sales amount, value and market share, market rivalry landscape, SWOT analysis and development plans for the next coming years To examine competitive progress such as expansions, arrangements, new product launches and acquisitions on the market

Access Exclusive Free Sample Report (COVID-19 Impact Analysis Updated Edition): Click Here> Download Sample Report of Stem Cell Assay Market Report 2020 (Pandemic Impact Analysis Updated Edition May 2020)

Follow is the chapters covered in Stem Cell Assay Market: Chapter 1 Stem Cell Assay Market Overview Chapter 2 COVID 19 Impact Chapter 3 Stem Cell Assay Segment by Types (Product Technology) Chapter 4 Global Stem Cell Assay Segment by Application Chapter 5 Global Stem Cell Assay Market by Regions (2015-2027) Chapter 6 Global Stem Cell Assay Market Competition by Manufacturers Chapter 7 Company (Top Players) Profiles and Key Data Chapter 8 Global Stem Cell Assay Revenue by Regions (2015-2020) Chapter 9 Global Stem Cell Assay Revenue by Types Chapter 10 Global Stem Cell Assay Market Analysis by Application Chapter 11 North America Stem Cell Assay Market Development Status and Outlook Chapter 12 Europe Stem Cell Assay Market Development Status and Outlook Chapter 13 Asia Pacific Stem Cell Assay Market Development Status and Outlook Chapter 14 South America Stem Cell Assay Market Development Status and Outlook Chapter 15 Middle East & Africa Stem Cell Assay Market Development Status and Outlook Chapter 16 Stem Cell Assay Manufacturing Cost Analysis Chapter 17 Marketing Strategy Analysis, Distributors/ Traders Chapter 18 Global Stem Cell Assay Market Forecast (2020-2027) Chapter 19 Research Findings and Conclusion Get detailed TOC for Stem Cell Assay Market Report @ https://cognitivemarketresearch.com/medical-devicesconsumables/stem-cell-assay-market-report#table_of_contents.

Customization of the Report: This report can be customized to meet the clients requirements. Please connect with our sales team, who will ensure that you get a report that suits your needs. You can also get in touch with our executives on to share your research requirements.nicolas.shaw@cognitivemarketresearch.com or call us on +1-312-376-8303.

About Us: Cognitive Market Research is one of the finest and most efficient Market Research and Consulting firm. The company strives to provide research studies which include syndicate research, customized research, round the clock assistance service, monthly subscription services, and consulting services to our clients. We focus on making sure that based on our reports, our clients are enabled to make most vital business decisions in easiest and yet effective way. Hence, we are committed to delivering them outcomes from market intelligence studies which are based on relevant and fact-based research across the global market. Contact Us: +1-312-376-8303 Email: nicolas.shaw@cognitivemarketresearch.com Web: https://www.cognitivemarketresearch.com

**********Download the Entire Report************************************************* https://cognitivemarketresearch.com/medical-devicesconsumables/stem-cell-assay-market-report

Go here to see the original:
Global Stem Cell Assay Market Growth is Projected to Grow at Sluggish Rate by 2027 Post COVID 19 Pandemic Merck, Thermo Fisher Scientific, GE...

NCRM NICHE International Stem Cell meet is going virtual in 2020 – Times of India

Active Knowledge Gaining event Fujio Cup Quiz (FCQ) in Japan, open to global talents

Tokyo, 15, July, 2020: The XV edition of NCRM NICHE (www.ncrmniche.org), on Stem Cells and Regenerative Medicine, incorporating the exclusive, active knowledge gaining event, The Fujio Cup Quiz, conducted regularly since 2006 every October, will be conducted this year as a virtual event, opening doors for scholars from all over the world to participate, according to the organizers, M/s GN Corporation (GNC) & JBM Inc., Japan.

Two levels of prelims between 2nd ~ 20th August and the final rounds of the Fujio Cup Quiz (FCQ) between 1st to 30th September, will be conducted through a virtual platform. The winners will share their winning story along with a presentation on stem cell research on the 18th & 19th October 2020, during the NCRM NICHE event, the inaugural anniversary commemorative event of Nichi-In Centre for Regenerative Medicine (NCRM), a Japan centred research institute working on cell-based therapies and novel biomaterial technologies. The Organizers are planning to invite the winners of the Fujio Cup 2020 to Japan depending on the ease down of COVID-19 related restrictions, tentatively in 2021, when they will be visiting top institutes working on cutting edge technologies in regenerative medicine in Tokyo, including the Edogawa Evolutionary Lab of Science (EELS, http://www.eels.tokyo).

The rapidly evolving specialty of regenerative medicine has phenomenal potentials to yield novel solutions to unmet medical needs; is an inter-disciplinary field in which chemists making scaffolds, physicists working on physical forces and biologists working on cell culture and tissue engineering have to collaborate amongst themselves and with physicians of various clinical specialities to develop innovative treatment options. Such path-breaking solutions need to be developed over a period of time, through ceaseless interactions among scientists of various domains & NCRM NICHE has been serving continuously as a platform for such inter-disciplinary interaction among budding scientists and clinicians over the past 15 years. Osteoarthritis affected knee joint of elderly, yielding cartilage tissue expressing pluripotency biomarkers when grown in the lab (https://doi.org/10.1016/j.reth.2020.03.006), is an out of the box solution with numerous potentials to revolutionize cell therapy options for cartilage damage caused by sports injury as well that develops with age related wear and tear; an outcome of NCRM NICHE & Fujio Cup Quiz, according to Dr. Shojiro Katoh, Chief Orthopaedic Surgeon & President, Edogawa Hospitals and head of EELS.

Yesteryear participants of Fujio Cup Quiz have become scholars of prestigious institutes of global eminence including Massachusetts General Hospital and Harvard Medical School, University of Toronto, MD Anderson Cancer Center, Berlin-Brandenburg School for Regenerative Therapies & Tokyo University. Fujio Cup Quiz alumni also have a priority channel for nomination of the Edogawa NICHE prize (www.edogawanicheprize.org), award, established in 2018, which honours individuals who are physicians and/or scientists from around the world chosen by the Jinseisha-NCRM committee, based on their contribution to development of a novel solution that enables prevention or diagnosis or treatment of any disease, through an inter-disciplinary interaction among different fields of science. The 2018 Edogawa NICHE Prize was awarded to Prof. James Edgar Till for his discovery of stem cells & the 2019 Edogawa NICHE Prize was awarded to Dr. Steven A. Rosenberg, for his pioneering work in developing effective adoptive immunotherapies to tackle cancer. The recipient of 2020 Edogawa NICHE Prize will be announced on the 15th of August and the commemorative lecture of the awardee is also planned together with the visit of FCQ winners to Japan in 2021.

Undergraduate, Postgraduate and Doctoral (PhD) students of Life Sciences, Biotechnology, Veterinary Science, Dentistry and Medicine between the ages of 20 and 32 years, registered in an accredited academic institute from any country that is a member state of the United Nations (UN) are eligible to participate in the Fujio Cup Quiz (FCQ). NCRM NICHE has an Oral Presentation session, in which all original works on Basic Sciences, Translational Studies and Clinical studies in the field of Stem Cells and Regenerative Medicine including the allied fields of Cell Biology, Cancer Biology, Immunotherapy and Cell based therapies are eligible for submission as abstracts. Selected abstracts will have an opportunity for virtual presentation on 18th & 19th of October, 2020.

30th of July, 2020 is the deadline for submission of abstracts & FCQ registration. Further details at https://www.ncrmniche.org/ncrmniche2020/registration.html

Prof. Masaharu Seno from Okayama University, Japan working on Development of Cancer stem cells from induced pluripotent stem cells (iPSCs) prepared from fibroblasts and Dr. Maria Cristina Nostro from University of Toronto working on generating functional cells from human pluripotent stem cells will be delivering virtual lectures in the plenary session of the event scheduled on 18th of October, 2020.

Institutes who wish to send their students and scholars for participation in the event and also those who wish to have a live broadcast of this event in their institute or to their students through their virtual platforms may contact us at webmaster@ncrmniche.org

For queries contact,

Mr. K. John Victor,

Consultant,

GN Corporation, Japan

kjv@gncorporation.com

The XIII edition of Fujio Cup Quizs Winners, Ms. Grace Aprilia Helena & Mr. Tommy Octavianus from Bandung Institute of Technology, Indonesia, receiving the ever-rotating cup from Dr Masahiro Katoh Chairman, Edogawa Hospital & Jinseisha Social Welfare Trust in Tokyo, Japan

An inter-continental team of 2019 NCRM NICHE delegates during a Japanese traditional Kimono wearing ceremony followed by a group picture on the final day of the event in Shibaura Institute, Tokyo, Japan

The 2019 Edogawa NICHE Prize award ceremony in University of Toronto; Dr Steven Rosenberg with the medal and plaque awarded by Prof. Gary Levy (3rd from Left) beside them are Dr Shojiro Katoh (Left) and Prof. Atul Humar, Chair, Multi-organ transplant program, University of Toronto (Right).

Disclaimer: Content Produced by GN Corporation Co Ltd

See more here:
NCRM NICHE International Stem Cell meet is going virtual in 2020 - Times of India